As a leading CRO company in Indonesia, Prodia the CRO keeps on taking steps forward and strives to be in our best potential. Being the award-winner of this category for 2 years in a row increases our confidence as well as our eagerness to improve our services, to adapt more and dive deeper into this industry and give better support to our customers and partners.
Referring to Frost & Sullivan’s report, Asia-Pacific’s (APAC) contract research organization (CRO) space has matured since the COVID-19 pandemic. The region’s significance in the industry is due to a notable increase in clinical research activities, particularly during the pandemic. Thanks to evolving trial dynamics, countries like Indonesia increasingly draw drug sponsors and CROs with well-developed infrastructure and diverse demographics. Prodia the CRO with our expertise and established networking across the country, and through our local-wise understanding about the clinical trial environment, always try to ensure that the desired goal of the clinical trials which is to obtain the best research outcome in the most effective way, efficient cost and timeline, without neglecting the rights of the patients and ethical aspects of the procedures, could be reached by great trial management throughout project preparation and conduct.
This recognition is the result of many individuals: hard work of our employees, and ultimately, the trust of our customers, partners, and investors who make critical decisions every day to support Prodia the CRO and contribute to our future. Thank you for believing in Prodia the CRO.
